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DNA bindingAbstract Mushrooms are known to complement chemotherapy and radiation therapy by counter-
ing the side effects of cancer. Recently, there has been great interest in isolation of novel bioactive
compounds from mushrooms due to their numerous health beneﬁcial effects. Chemically
water-extractable polysaccharide (MFKF-AP1b), with a molecular weight of 12 kDa, was isolated
from fruiting bodies of mushroom Fomes fomentarius. In this research, we investigated the
anti-tumor effects of MFKF-AP1b on human lung carcinoma A549 cells. Results showed that
MFKF-AP1b markedly inhibited A549 cell growth in a dose-dependent manner based on the
amount of lactate dehydrogenase (LDH) released and morphological alterations. In addition,
MFKF-AP1b induced cellular apoptosis by causing single-stranded DNA breakage, as evidenced
by apoptosis assay. Furthermore, MFKF-AP1b (25–100 lg/ml) signiﬁcantly induced single-
stranded DNA breakage in A549 cells, as shown by comet assay. Taken together, our results dem-
onstrate that MFKF-AP1b has strong anti-tumor effects mediated through induction of apoptosis.
Therefore, MFKF-AP1b could be useful in lung chemotherapy.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Lung cancer has become the most common cause of cancer-
related death in both men and women, accounting for 28%
of all cancer-related deaths in the U.S. (Cardenal et al.,
1999). Although treatment of lung cancer has improved, mor-
tality remains high in lung cancer patients. A growing body of
research suggests that naturally occurring compounds can act
as antioxidants as well as cancer preventative and therapeutic
agents (Parkin et al., 1999; Rahman et al., 2005; Hashibe et al.,
2007). Development of chemotherapeutic agents with maximal
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able route for cancer management. In this context, mushrooms
play a pivotal role as anti-tumor agents. Edible mushrooms
have been used as health nutritional supplements for several
centuries, and they complement chemotherapy and radiation
therapy by countering the side effects of cancer (Mizuno
et al., 1995).
The bioactive compounds in mushrooms responsible for
their anti-tumor potential include polysaccharides, proteins,
fats, ash, glycosides, alkaloids, volatile oils, tocopherols, phen-
olics, ﬂavonoids, carotenoids, folates, ascorbic acid enzymes,
and organic acids (Mizuno et al., 1992, 1995; Jong and
Birmingham, 1993; Ferreira et al., 2009). Among these bioac-
tive compounds, polysaccharides are the most well-known and
most potent mushroom-derived substances with anti-tumor
activity (Ferreira et al., 2010). In this study, we analyzed the
anti-tumor activity of a polysaccharide (MFKF-AP1b) iso-
lated from fruiting bodies of the medicinal mushroom Fomes
fomentarius in human lung cancer A549 cells.
F. fomentarius, a basidiomycete fungus, has been used as a
traditional Chinese and Korean medicine for many centuries
for the treatment of various diseases, including oral ulcers, gas-
troenteric disorders, hepatocirrhosis, inﬂammation, and vari-
ous cancers. Recent studies have shown that F. fomentarius
has antioxidant, anti-inﬂammatory, and anti-diabetic activities
(Lee, 2005; Park et al., 2004). However, there are few reports
on the apoptotic activity of F. fomentarius (Ito et al., 1976;
Chen et al., 2008).
To discover novel agents fromnatural products that improve
the therapeutic outcome of cancer, we tested the anti-tumor
effects of a polysaccharide (MFKF-AP1b) isolated from F.
fomentarius on A549 lung cancer cells. Speciﬁcally, we tested
the apoptotic activity of MFKF-AP1b in lung carcinomas.
2. Materials and methods
2.1. Reagents
RPMI 1640, HEPES, staurosporine, Hoechst 33342, and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
were purchased from Sigma–Aldrich, St. Louis, USA. Fetal
bovine serum was supplied by Gibco, USA. All solvents were
HPLC grade and supplied by J.T. Baker (Phillipsburg, NJ,
USA).
2.2. Materials
Chemically water-extractable polysaccharide (MFKF-AP1b)
was isolated from hot water extracts of fruiting bodies of
mushroom F. fomentarius by successive DEAE-Sepharose FF
and concanavalin A-Sepharose 4B column chromatography.
Molecular weight of MFKF-AP1b was estimated to be about
12 kDa by high performance liquid chromatography (HPLC)
(Park et al., 2013). Solutions of MFKF-AP1b (25–100 lg/ml)
were prepared in a water/methanol mixture (1:1, v/v).
2.3. Cell culture
Lung cancer cells A549 (KCLB) were cultivated in RPMI
1640 medium supplemented with 25 mM HEPES buffer,
25 mM sodium bicarbonate, 300 mM L-glutamate, and 10%heat-inactivated fetal bovine serum (Gibco, USA) in a CO2
incubator (5% CO2 in air) at 37 C. For the experiment, cells
were cultured in 12-well plates at 1 · 106 cells/well. Cells were
treated with several concentrations of MFKF-AP1b (25, 50,
and 100 lg/ml) for 24 h. As a positive control, 1 lM stauro-
sporine (Sigma, St. Louis, USA) was added for 4 h to induce
apoptosis. Cells were then centrifuged (600g · 3 min) and
harvested.
2.4. MTT assay and cell morphology
Cell viability was measured by MTT bioassay. Brieﬂy, A549
cells (1 · 106 cells/well) were seeded in each well of a 96-well
plate for 24 h. After incubation with different concentrations
of MFKF-AP1b for 24 h, 10 ll of MTT solution (5 mg/ml
on PBS) dissolved in PBS was added and incubated for 4 h.
After color development, 100 ll of DMSO was applied. Absor-
bance was measured using an ELISA plate reader (Bio-Tek
Instrument Co., WA, USA) at 540 nm. The viability% was
measured using formula-
Sample absorbance=Control absorbance 100:2.5. Lactate dehydrogenase (LDH) assay
A549 cells (1 · 106 cells/well) were seeded in each well of a 96-
well plate for 24 h. After incubation with different concentra-
tions of MFKF-AP1b for 24 h, medium was collected and
cleared by centrifugation. After supernatants were collected,
cytotoxicity was quantiﬁed by measuring the amount of total
LDH released by cells using an LDH assay kit (Sigma–
Aldrich, St. Louis, USA) according to the manufacturer’s pro-
tocol. Brieﬂy, LDH, a glycolytic enzyme, is concerned with the
reduction of pyruvic acid in the presence of dihydronicotina-
mide adenine dinucleotide (NADH). LDH assay reagent was
added to supernatants and incubated for up to 30 min at room
temperature in the dark, after which the reaction was stopped
by adding 1 N HCl. The absorbance of samples was measured
at 450 nm.
2.6. Assay for nuclear apoptosis (Hoechst staining)
To determine DNA chromatin morphological features, cells
were treated with Hoechst 33342 stain according to Diaz-
Ruiz et al., 2001. Brieﬂy, cells were cultured and treated for
24 h with different concentrations of MFKF-AP1b and stauro-
sporine (1 lM) for 4 h. After washing twice in PBS, cells were
ﬁxed with cold 4% formaldehyde. Cells were then washed with
PBS again and incubated with Hoechst 33342 (1 lg/ml) at
37 C for 10 min. After washing with PBS, cells were analyzed
under a ﬂuorescence microscope (Nikon Eclipse TS100 Epi-
ﬂuorescence microscope, Japan).
2.7. Comet assay
To evaluate DNA damage, comet assay was performed
according to Singh et al. (1988), with some modiﬁcations.
A549 lung cancer cells treated with MFKF-AP1b and
staurosporine were harvested by washing twice with phos-
phate-buffered saline (PBS) and then suspended in 70 ll of
1% (w/v) low melting point agarose in PBS, pH 7.4, at
Figure 1 Effect of MFKF-AP1b on viability of A549 lung
cancer cells. The viability of cells pretreated with 1 lM stauro-
sporine (positive control) and MFKF-AP1b at different concen-
trations (25, 50, and 100 lg/ml) for 24 h was estimated using MTT
assay after being cultured for 24 h. Data are represented as the
mean ± SD of three independent experiments. An asterisk indi-
cates *p< 0.05, **p< 0.01, ***p< 0.001.
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glass microscope slides pre-coated with a layer of 1% (w/v)
normal melting point agarose, after which the third layer com-
posed of 75 ll of 0.5% (w/v) low melting point agarose simi-
larly prepared in PBS was applied. The agarose was allowed
to set for 10 min on ice. To remove cellular proteins, slides
were immersed in lysis solution (2.5 M NaCl, 0.1 M Na2-
EDTA, 10 mM Tris, pH 10.0, with NaOH, 10% v/v dimethyl
sulfoxide, and 1% v/v Triton X-100) at 4 C for 1 h. Slides
were then placed in a electrophoresis tank containing electro-
phoresis buffer (0.3 M NaOH and 1 mM Na2EDTA) for
30 min before electrophoresis at 40 V for 40 min. The slides
were then washed with neutralizing solution (0.4 M Tris–
HCl, pH 7.5) for 20 min before staining with 50 ll of ethidium
bromide (20 mg/ml), and analyzed visually with a Nikon EPI
ﬂuorescence microscope (Japan).
2.8. Measurement of single-stranded DNA
As DNA in apoptotic cells is sensitive to formamide, dena-
tured DNA was detected by a monoclonal antibody against
single-stranded DNA using an ApoStrand ELISA apoptosis
detection kit (Enzo Life Sciences, Plymouth Meeting, PA,
USA) according to the manufacturer’s protocol. Brieﬂy,
1.0 · 106 cells were cultured in a 96-well microplate and treated
with different concentrations of MFKF-AP1b. After 12 h, cells
were ﬁxed and dried for attachment to the plate surface. Cells
were then treated with formamide and heated at 56 C for
30 min, followed by incubation with an antibody mixture for
30 min after blocking non-speciﬁc binding sites. After washing,
peroxidase substrate was added to each well, and the absor-
bance was measured at 405 nm using an ELISA reader (Bio-
Tek Instrument Co., WA, USA).
2.9. Statistical analysis
Each experimental condition was analyzed at least in triplicate
(n= 3). Data were expressed as the mean ± standard devia-
tion (S.D.). Statistical analyses were carried out using
Student’s t-test. Differences were considered statistically
signiﬁcant at *p< 0.05, **p< 0.01, ***p< 0.001.
3. Results
3.1. Anti-proliferative effects of MFKF-AP1b on A549 cells
We characterized the anti-proliferative effects of MFKF-AP1b
on A549 cells by measuring cell viability using MTT assay.
Cultures of A549 cells were treated with MFKF-AP1b at con-
centrations of 25, 50, and 100 lg/ml for 24 h. As shown in
Fig. 1, MFKF-AP1b inhibited proliferation of A549 cells. Cell
viability was lowest (59.22 ± 5.17%) after 24 h of MFKF-
AP1b treatment at a concentration of 100 lg/ml, as compared
to MFKF-AP1b concentrations of 25 and 50 lg/ml
(64.46 ± 1.48% and 65.73 ± 1.24%, respectively).
3.2. Cytotoxic effects of MFKF-AP1b
To better characterize the cytotoxicity of MFKF-AP1b in
human lung cancer cells (A549), we performed cellular lactatedehydrogenase (LDH) release assay. In this experiment, intra-
cellular LDH released into culture medium was an indicator
of cytotoxicity. A549 cells treated with 25, 50, and 100 lg/ml
of MFKF-AP1b for 24 h showed a dose-dependent increase in
LDHactivity, indicating cellular damage. Further, LDH release
into culture mediumwas highest upon treatment with 100 lg/ml
of MFKF-AP1b (43.74 ± 1.19%), which induced A549 cell
death through cytotoxicity (Fig. 2). A signiﬁcantly lower
amount of LDH was released at concentrations of 25 and
50 lg/ml (39.91 ± 1.19% and 40.25 ± 1.29%, respectively).
3.3. MFKF-AP1b induces signiﬁcant morphological alterations
The cytotoxic effects of MFKF-AP1b were also reﬂected in the
morphological appearance of A549 cells after 24 h (Fig. 3).
Treatment with 1 lM staurosporine and 100 lg/ml of
MFKF-AP1b had a marked effect on cellular morphology,
as cells became more round and refractile under a microscope.
Cells treated with 100 lg/ml of MFKF-AP1b became apopto-
tic bodies and eventually detached from the surface, whereas
untreated cells (control) remained well spread with a ﬂattened
morphology. Treatment with 50 lg/ml of MFKF-AP1b had a
comparatively weaker effect, and 25 lg/ml of MFKF-AP1b
had no discernible effect. These results suggest that MFKF-
AP1b-treated human lung cancer cells undergo cell death
and exhibit morphological features suggestive of apoptosis.
3.4. MFKF-AP1b potentiates cellular apoptosis
To determine whether or not the above results can be attrib-
uted to apoptosis of A549 cells, we performed chromatin
condensation assay using Hoechst 33342 visualized by
Figure 2 Lactate dehydrogenase (LDH) release assay. There was
a signiﬁcant increase in LDH release from lung cancer cells as
measured by colorimetric assay. Pretreatment with 1 lM stauro-
sporine (positive control) and MFKF-AP1b at different concen-
trations (25, 50, and 100 lg/ml) for 24 h signiﬁcantly increased
LDH release from A549 cells as a measure of cytotoxicity. Data
are represented as the mean ± SD of three independent experi-
ments. An asterisk indicates **p< 0.01.
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revealed a greater number of apoptotic cells showing charac-
teristic morphologic alterations such as nucleic shrinkage and
formation of pycnonuclei following treatment with 100 lg/ml
of MFKF-AP1b and staurosporine for 24 h compared to the
control group.
3.5. MFKF-AP1b induces DNA fragmentation in A549 cells
Degradation of DNA into multiple internucleosomal frag-
ments of 180–200 base pairs is a distinct biochemical hallmarkFigure 3 Morphological changes induced by (A) control, (B) 1 lM
MFKF-AP1b, and (E) 100 lg/ml of MFKF-AP1b in A549 lung canceof apoptosis. To detect this, we performed single cell gel elec-
trophoresis (comet assay), which is a sensitive technique that
allows detection of DNA strand breaks. Cells treated with
staurosporine and MFKF-AP1b showed comet formation in
a dose-dependent manner, whereas untreated cells did not
show any comet-like appearance (Fig. 5). To further determine
whether or not DNA fragmentation is typical of apoptosis, we
performed apoptosis detection assay using an ApoStrand
ELISA apoptosis detection kit, which detects in vitro single-
stranded DNA breaks induced by MFKF-AP1b treatment.
The sensitivity of this assay reﬂects changes in chromatin
structure associated with apoptosis, such as chromatin conden-
sation and digestion of proteins stabilizing DNA. As shown in
Fig. 6, treatment with MFKF-AP1b at concentrations of 25,
50, and 100 lg/ml for 24 h signiﬁcantly increased the apoptotic
rate of A549 cells in a dose-dependent manner. Taken
together, these results indicate that, apart from its cytotoxic
effects, MFKF-AP1b can induce apoptosis in A549 cells.
4. Discussion
Cancer remains one of the major causes of death worldwide.
The most effective treatment strategy for cancer is cytotoxic
agent-based chemotherapy, which increases patient survival
but also has side effects that severely limit its clinical effective-
ness such as acquisition of drug resistance (Appel et al., 2007;
Rutkoski and Raines, 2008; Lal et al., 2011). Therefore, novel
therapeutic strategies involving natural compounds could
reduce the cumulative effects of chemotherapy by enhancing
anti-tumor activities. The present paper evaluated the effects
of MFKF-AP1b, a dietary polysaccharide from medicinal
mushroom F. fomentarius, on a human lung adenocarcinoma
cell line (A549) in relation to cell growth inhibition and apop-
tosis induction. The anti-tumor activities of polysaccharides
isolated from medicinal fungi are very attractive due to their
low toxicity in normal cells and their apparent lack of side
effects in clinical patients (Fukushima, 1989).staurosporine, (C) 25 lg/ml of MFKF-AP1b, (D) 50 lg/ml of
r cells after 24 h of treatment.
Figure 4 Representative nuclear stained images of A549 cells following treatment with different concentrations of MFKF-AP1b (25, 50,
and 100 lg/ml) and 1 lM staurosporine observed under a ﬂuorescence microscope at a magniﬁcation of 40·. (A) Control; (B) treated with
staurosporine; (C–E) MFKF-AP1b 25, 50, and 100 lg/ml, respectively.
Figure 5 Representative Comet images of A549 cells following treatment with different concentrations of MFKF-AP1b (25, 50, and
100 lg/ml) and staurosporine (1 lM). (A) Control; (B) treated with staurosporine; (C–E) MFKF-AP1b (25, 50, and 100 lg/ml,
respectively).
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effect for MFKF-AP1b in lung cancer cells. Exposure to
MFKF-AP1b for 24 h resulted in dose-dependent inhibition
of A549 cell growth, as evidenced by cell morphological alter-
ations (Fig. 3). Further, MFKF-AP1b reduced cellular meta-
bolic activity of A549 cells and potentiated cytotoxic activity
via LDH release into the medium (Fig. 3). Up to this point,the mode of cell death responsible for these results was uncon-
ﬁrmed. Autophagy, apoptosis, and necrosis are all different
types of cell death, and apoptosis is the desired mode of cell
death in chemotherapy (Amos et al., 1998). Recently, studies
have extensively focused on the apoptotic potential of com-
pounds as anti-tumor agents (Rosse et al., 1998). In the current
study, we investigated whether or not the cytotoxic effects of
Figure 6 Induction of cell death by MFKF-AP1b. A549 cells
were treated with 1 lM staurosporine and MFKF-AP1b (25, 50,
and 100 lg/ml), after which amount of single-stranded DNA was
detected by an ApoStrand ELISA apoptosis detection kit. An
asterisk indicates *p< 0.05, **p< 0.01.
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examining cellular changes associated with apoptosis using
comet assay, Hoechst staining, and apoptosis assay.
Induction of apoptosis is a common mechanism of anti-
tumor drugs (Ahmad et al., 2010). Here, we detected apoptotic
cells by comet assay with ethidium bromide staining as well as
apoptosis assay, which detects formation of single-stranded
DNA breaks (Figs. 5 and 6, respectively). MFKF-AP1b-trea-
ted cells exhibited a dose-dependent increase in nuclear chro-
matin staining, as visualized by Hoechst 33342 (Fig. 4),
including morphological characteristics of apoptotic cells such
as increased nuclear condensation, nuclear shrinkage, and pyc-
nonuclei formation. In the current study, both Hoechst stain-
ing and comet assay conﬁrmed that proportions of apoptotic
cells dramatically increased in a dose-dependent manner upon
MFKF-AP1b treatment compared with staurosporine or con-
trol cells (Figs. 4 and 5). Therefore, MFKF-AP1b can potenti-
ate cytotoxicity by promoting apoptosis in cancer cells.
The ability of polysaccharides to induce apoptosis in cancer
cells can differ greatly according to their chemical composition
and conﬁguration as well as their physical properties.
Although it is difﬁcult to correlate the structure and anti-
tumor activity of complex polysaccharides, a relationship can
be inferred. It has been suggested that structural features in
the main chain of the glucan such as b-(1ﬁ3) linkages as well
as b-(1ﬁ6) branch points are needed for anti-tumor activity
(Miyazaki and Nishijima, 1981; Chihara, 1992). High
molecular weight glucans appear to be more effective than
low molecular weight species (Mizuno, 1996, 1999a,b). The
polysaccharide used in the present study was a partially puri-
ﬁed polysaccharide fraction with an average molecular weight
of over 12 kDa. Its exact mechanism of action for activating
apoptosis remains to be identiﬁed.
5. Conclusion
In conclusion, our studies prove that MFKF-AP1b induces
cell death in A549 lung carcinoma cells in a dose-dependentmanner as well as apoptosis by elevation of LDH release, dis-
ruption of cellular morphology, and induction of nuclear dam-
age. However, further investigation about the relationship
between MFKF-AP1b-mediated cytotoxic and apoptotic path-
ways is needed.
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